<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03064854</url>
  </required_header>
  <id_info>
    <org_study_id>CPDR001C2101</org_study_id>
    <secondary_id>2016-002815-17</secondary_id>
    <nct_id>NCT03064854</nct_id>
  </id_info>
  <brief_title>PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients</brief_title>
  <official_title>Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum Doublet Chemotherapy and Other Immunooncology Agents in PD-L1 Unselected, Metastatic NSCLS Patients (ElevatION:NSCLC-101 Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to establish the maximum tolerated dose (MTD) and/or&#xD;
      recommended dose for expansion (RDE) of PDR001 when administered in combination with&#xD;
      platinum-doublet chemotherapy and other immunooncology agent(s) in treatment naive patients&#xD;
      with PD-L1 unselected, advanced NSCLC, and to estimate the preliminary anti-tumor activity in&#xD;
      this patient population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Actual">August 11, 2021</completion_date>
  <primary_completion_date type="Actual">July 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLTs) during the first 6 weeks of therapy</measure>
    <time_frame>42 days</time_frame>
    <description>A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first 42 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR) per local investigator assessment for groups A, B and C</measure>
    <time_frame>From baseline up to approximately 28 months</time_frame>
    <description>ORR is defined as the proportion of patients with best overall response (BOR) of complete response (CR) or partial response (PR), as per RECIST 1.1 and local investigator assessment for groups A, B and C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) per local investigator assessment for group E</measure>
    <time_frame>Up to approximately 28 months</time_frame>
    <description>ORR is defined as the proportion of patients with BOR of CR or PR, as per RECIST 1.1 and local investigator assessment for group E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) per Investigator</measure>
    <time_frame>From start of treatment to the date of the first documented progression or death due to any cause, whichever comes first, assessed up to approximately 28 months</time_frame>
    <description>PFS is defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause, as per RECIST 1.1 and local investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) per Investigator</measure>
    <time_frame>Up to approximately 28 months</time_frame>
    <description>DCR is the proportion of patients with a BOR of CR or PR or stable disease (SD), as per RECIST 1.1 and local investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per Investigator</measure>
    <time_frame>From date of first documented response to the first documented progression or death due to any cause, whichever comes first, assessed up to approximately 28 months</time_frame>
    <description>DOR is defined by responders as the time between the date of first documented response (CR or PR) and the date of first documented progression (RECIST 1.1 and local investigator assessment) or death due any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) per Investigator</measure>
    <time_frame>From start of treatment to the date of the first documented reponse (CR or PR), assessed up to approximately 28 months</time_frame>
    <description>TTR is defined as the time from the date of start of treatment to the first documented response of either CR or PR as per RECIST 1.1 and local investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>from date of start of treatment to date of death due to any cause (assessed up to approximately 3.5 years)</time_frame>
    <description>OS is defined as the time from date of start of treatment to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma Concentration (Ctrough) of PDR001</measure>
    <time_frame>Pre-infusion on Day 1 of Cycle 1 to 4 of induction phase; pre-infusion on Day 1 of Cycle 1 to 4, 6, 8 and every 6 cycle afterwards of maintenance phase; Cycle = 21 Days</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma Concentration (Ctrough) of chemotherapy</measure>
    <time_frame>Pre-infusion on Day 1 of Cycle 1, 3 and 4 of induction phase; Cycle = 21 Days</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis. Ctrough will be assessed for all chemotherapy agents: cysplatin, pemetrexed, carboplatin and gemcitabine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma Concentration (Ctrough) of canakinumab</measure>
    <time_frame>Pre-infusion on Day 1 of Cycle 1, 3 and 4 of induction phase; Cycle = 21 Days</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDR001 Antidrug antibodies (ADA) prevalence at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood samples will be collected at indicated time points for immunogenicity analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Canakinumab ADA prevalence at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood samples will be collected at indicated time points for immunogenicity analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDR001 ADA incidence during treatment</measure>
    <time_frame>Pre-infusion on Day 1 of Cycle 1 to 4 of induction phase, pre-infusion on Day 1 of Cycle 1, 2, 3, 4, 6, 8 and every 6 cycle afterwards of maintenance phase, end of treatment and 30 and 150-day post-treatment</time_frame>
    <description>Blood samples will be collected at indicated time points for immunogenicity analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Canakinumab ADA incidence during treatment</measure>
    <time_frame>Pre-infusion on Day 1 of Cycle 1 and 4 of induction phase, pre-infusion on Day 1 of Cycle 6, 14 and 20 of maintenance phase, end of treatment and 30 and 150-day post-treatment</time_frame>
    <description>Blood samples will be collected at indicated time points for immunogenicity analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>through study completion, up to approximately 3.5 years</time_frame>
    <description>Incidence of AEs (CTCAE v4.03)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Group A: squamous, gem/cis+PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: non-squamous, pem/cis+PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: paclitaxel/carbo+PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>Powder for solution for infusion</description>
    <arm_group_label>Group A: squamous, gem/cis+PDR001</arm_group_label>
    <arm_group_label>Group B: non-squamous, pem/cis+PDR001</arm_group_label>
    <arm_group_label>Group C: paclitaxel/carbo+PDR001</arm_group_label>
    <arm_group_label>Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Group A: squamous, gem/cis+PDR001</arm_group_label>
    <arm_group_label>Group B: non-squamous, pem/cis+PDR001</arm_group_label>
    <arm_group_label>Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Group A: squamous, gem/cis+PDR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Group B: non-squamous, pem/cis+PDR001</arm_group_label>
    <arm_group_label>Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Group C: paclitaxel/carbo+PDR001</arm_group_label>
    <arm_group_label>Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Group C: paclitaxel/carbo+PDR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canakinumab</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Patient has stage IIIB (and is not a candidate for definitive multimodality therapy)&#xD;
             or has stage IV NSCLC or relapsed locally advanced or metastatic NSCLC as follows:&#xD;
&#xD;
               1. Group A, group B and group C only: Patients not previously treated with any&#xD;
                  systemic anti-cancer therapy (e.g. cytotoxic drugs, targeted therapy, monoclonal&#xD;
                  antibody therapy including immunotherapy (e.g. PD-1/PD-L1 inhibitors) or targeted&#xD;
                  therapies, either experimental or not), with exception of neo-adjuvant or&#xD;
                  adjuvant therapy as depicted in inclusion criterion 4.&#xD;
&#xD;
               2. Group D only: Patients who have received only one prior systemic therapy&#xD;
                  treatment consisting of a PD-1 and/or PD-L1 inhibitor with or without a CTLA4&#xD;
                  inhibitor for NSCLC, with exception of neo-adjuvant or adjuvant therapy as&#xD;
                  depicted in inclusion criterion 4. The last dose of prior immunotherapy must have&#xD;
                  been administered at least 6 weeks prior to the start of study treatment (cycle 1&#xD;
                  day 1).&#xD;
&#xD;
          2. Histologically or cytologically confirmed diagnosis of NSCLC that is EGFR Wild-type,&#xD;
             ALK-negative rearrangement and ROS1-negative rearrangement&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          4. Patients with at least 1 measurable tumor lesion as assessed by Computed Tomography&#xD;
             (CT) Scan or Magnetic Resonance Imaging (MRI) according to RECIST 1.1.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Patient with a history of severe hypersensitivity reaction to the planned study&#xD;
             treatment including gemcitabine, paclitaxel, cisplatin, carboplatin, pemetrexed or any&#xD;
             known excipients of these drugs&#xD;
&#xD;
          2. History of severe hypersensitivity reactions to other monoclonal antibodies, which in&#xD;
             the opinion of the investigator may pose an increased risk of serious infusion&#xD;
             reaction.&#xD;
&#xD;
          3. Patient has history of interstitial lung disease or interstitial pneumonitis,&#xD;
             including clinically significant radiation pneumonitis (i.e., affecting activities of&#xD;
             daily living or requiring therapeutic intervention).&#xD;
&#xD;
          4. History of leptomeningeal metastases&#xD;
&#xD;
          5. Active, known or suspected autoimmune disease or a documented history of autoimmune&#xD;
             disease, including ulcerative colitis and Crohn's disease (Patients with vitiligo,&#xD;
             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only&#xD;
             requiring hormone replacement, psoriasis not requiring systemic treatment, or&#xD;
             conditions not expected to recur in the absence of an external trigger are permitted&#xD;
             to enroll).&#xD;
&#xD;
          6. Use of any live vaccines against infectious diseases within 4 weeks of initiation of&#xD;
             study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Santa Monica Hematology / Oncology SC-2</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center SC</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System SC</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine SC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon Cedex</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille cedex 05</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>February 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2017</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PDR001</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>lung</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

